Acumen Pharmaceuticals, Inc. (ABOS)

Market Cap	154.46M +102.4%
Revenue (ttm)	n/a
Net Income	-121.34M
EPS	-2.00
Shares Out	60.57M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	735,275
Open	2.560
Previous Close	2.630
Day's Range	2.359 - 2.750
52-Week Range	0.855 - 3.600
Beta	0.21
Analysts	Strong Buy
Price Target	7.75 (+203.92%)
Earnings Date	Mar 26, 2026

About ABOS

Acumen Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops targeted therapies for the treatment of Alzheimer’s disease. The company focuses on advancing a targeted immunotherapy drug candidate Sabirnetug (ACU193), a recombinant humanized immunoglobulin gamma 2, which has completed the INTERCEPT-AD phase 1 clinical trial and in ALTITUDE-AD phase 2 clinical trial to target soluble amyloid-beta oligomers. It has a collaboration and license agreement with Halozyme, Inc. for the development of a subcutaneous formulation of Sa...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Jul 1, 2021
• Employees: 61
• Stock Exchange: NASDAQ
• Ticker Symbol: ABOS
• Website: https://acumenpharm.com

Analyst Summary

According to 4 analysts, the average rating for ABOS stock is "Strong Buy." The 12-month stock price target is $7.75, which is an increase of 203.92% from the latest price.

Price Target

$7.75

(203.92% upside)

Analyst Consensus: Strong Buy